The head of the Gamaleya Center Gunzburg announced the development of a drug from antibodies for patients with COVID in an interview with RIA Novosti that Russia is developing a drug from antibodies to treat patients with COVID-19.
“Here are antibodies that can be given to patients with coronavirus in the form of a medicine, we are now developing,” said the head of the center Gamalei.
According to Gunzburg, clinical trials of the drug for patients with coronavirus will begin in January, within three to four months they will be completed.
Earlier Gunzburg based on a study conducted jointly with the Department of Health Moscow, reported that for complete protection against the delta strain, 300 antibodies in international units are needed. He also noted that if this figure is lower, then you need to be vaccinated with Sputnik Light.
According to the headquarters on November 9, over the past day, 39 160 cases of coronavirus were detected in Russia. The total number of infections in the country for the entire time was 8,873,655.